

Remarks

After amendment, claims 40, 51-56 and 67-69 remain pending in the present application. Claims 68 and 69 are new. Claims 57-65 and claims 1-39 have been cancelled previously *without prejudice*. Support for the amendment to the claims can be found throughout the originally filed application and claims. No new matter has been added by way of this amendment.

Applicants note that any subject matter which is cancelled herein, including any subject matter canceled from previously pending claims is made *without prejudice* in order to give Applicant a chance to consider filing any one or more divisional/continuation applications to seek allowance of that subject matter. The present amendments have been made to expedite allowance of the instant application and in particular, to address the enablement issue associated with cancers that are other than solid tumors. The presently pending claims are now directed to the use of the compounds as claimed in treating solid tumors and cancers as otherwise set forth in the claims. The treatment of the claimed tumors/cancers as set forth in the claims is consistent with the activity of the claimed compounds as anti-angiogenesis agents. The previously presented declaration of Dr. Jack Arbiser was enclosed in support of the enablement of the present invention. The assays presented therein evidenced that solenopsin exhibits substantial antiproliferative activity in both cells assays which is consistent with its use as an anticancer agent as is claimed.

Given the rejection which is maintained, Applicants respectfully request an interview with Examiner Gullede prior to the issuance of a first office action in order to provide guidance to the present inventors in addressing the rejection.

Applicants also request that the Examiner consider the information disclosure statement filed in September, 2010.


RECEIVED
CENTRAL FAX CENTER

APR 28 2011

Applicants respectfully submit that the application is in condition for allowance and early action resulting in allowance of the instant application is earnestly solicited. Alternatively, Applicants respectfully request that the Examiner consider interviewing this application prior to a first office action in order to advance prosecution.


No fee is due for the presentation of this amendment. A request for continued examination (RCE) is enclosed as is authorization to charge Deposit Account 04-0838 \$405 for the request. Please charge any additional fee due or credit any overpayment previously made to Deposit Account No. 04-0838.

Respectfully submitted,


Henry D. Coleman
Reg. No. 32,559
714 Colorado Avenue
Bridgeport, Connecticut 06605
(203) 366-3560

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being sent by facsimile to Examiner Brian M. Gudgedge, in Group Art Unit 1612 of the United States Patent Office in Alexandria, VA 22313-1450 on April 28, 2011.


Henry D. Coleman, Reg. No. 32,559

S.N. 10/502,080
B40-002.PreliminaryAmendment 4-28-11

6